Pharmacogenomics of drug transporters: a new approach to functional analysis of the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1).
暂无分享,去创建一个
[1] T. Ishikawa,et al. The genetic polymorphism of drug transporters: functional analysis approaches. , 2004, Pharmacogenomics.
[2] G. Johnson,et al. Nature Encyclopedia of the Human Genome , 2004 .
[3] M. Fromm,et al. Genetic polymorphisms of the human MDR1 drug transporter. , 2003, Annual review of pharmacology and toxicology.
[4] P. Beaune,et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. , 2003, Journal of the American Society of Nephrology : JASN.
[5] E. Lee,et al. Frequency of C3435T single nucleotide MDR1 genetic polymorphism in an Asian population: phenotypic-genotypic correlates. , 2003, British journal of clinical pharmacology.
[6] 岡崎 修,et al. アクリルアミド及びIDPN(3,3'-Iminodipropionitrile)のラット28日間経口投与による神経行動毒性 : 統一プロトコールによる共同研究結果に基づく課題と検査法の解説 , 2003 .
[7] R. Kreienberg,et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer. , 2003, International journal of oncology.
[8] A. Sparreboom,et al. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. , 2003, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[9] R. Weinshilboum. Inheritance and drug response. , 2003, The New England journal of medicine.
[10] Howard L McLeod,et al. Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.
[11] E. Wiemer,et al. MDR‐1 C3435T gene polymorphism does not correlate with P‐Glycoprotein expression and function in acute myeloid leukemia , 2003 .
[12] L. Benet,et al. The effect of induction conditions and MDR1 genotypes on dicloxacillin pharmacokinetics , 2003 .
[13] L. Benet,et al. The functional change of P‐glycoprotein on lymphocytes under induction conditions as a function of MDRL polymorphisms , 2003 .
[14] June-Sung Lee,et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in subjects with known genotype of MDR1 3435C>T allele , 2003 .
[15] D. Hesselink,et al. Tacrolimus, but not cyclosporine drug levels, are correlated with CYP3A5*3 and CYP3A4*1B genotype; no correlation with the MDR‐1 C3435T polymorphism , 2003 .
[16] Y. Cheung,et al. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. , 2003, Pharmacogenetics.
[17] P. Harrigan,et al. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response , 2003, AIDS.
[18] F. Sharom,et al. Transition state P-glycoprotein binds drugs and modulators with unchanged affinity, suggesting a concerted transport mechanism. , 2003, Biochemistry.
[19] U. Brinkmann,et al. Dipyridamole enhances digoxin bioavailability via P‐glycoprotein inhibition , 2003, Clinical pharmacology and therapeutics.
[20] P. Syrris,et al. Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and p-glycoprotein correlate with dose requirement , 2002, Transplantation.
[21] E. Maiorano,et al. Expression of P-Glycoprotein in Human Cerebral Cortex Microvessels , 2002, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[22] Werner Siegmund,et al. The effects of the human MDR1 genotype on the expression of duodenal P‐glycoprotein and disposition of the probe drug talinolol , 2002, Clinical pharmacology and therapeutics.
[23] U. Brinkmann,et al. Modulation of steady‐state kinetics of digoxin by haplotypes of the P‐glycoprotein MDR1 gene , 2002, Clinical pharmacology and therapeutics.
[24] M. Kasuga,et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. , 2002, Biological & pharmaceutical bulletin.
[25] B. Goh,et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Kim,et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. , 2002, Cancer research.
[27] Keizo Sugimachi,et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene , 2002, Transplantation.
[28] Miyuki Kimura,et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P‐glycoprotein , 2002, Clinical pharmacology and therapeutics.
[29] S. Uemoto,et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. , 2002, Pharmacogenetics.
[30] R. Kim. MDR1 single nucleotide polymorphisms: multiplicity of haplotypes and functional consequences. , 2002, Pharmacogenetics.
[31] Kun Tang,et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. , 2002, Pharmacogenetics.
[32] M. Gottesman,et al. Functional characterization of coding polymorphisms in the human MDR1 gene using a vaccinia virus expression system. , 2002, Molecular pharmacology.
[33] E. Ezan,et al. A high-throughput screening microplate test for the interaction of drugs with P-glycoprotein. , 2002, Analytical biochemistry.
[34] D. Min,et al. C3435T Mutation in Exon 26 of the Human MDR1 Gene and Cyclosporine Pharmacokinetics in Healthy Subjects , 2002, Therapeutic drug monitoring.
[35] S. Ekins,et al. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. , 2002, Molecular pharmacology.
[36] S. Ekins,et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. , 2002, Molecular pharmacology.
[37] U. Hofmann,et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. , 2002, British journal of clinical pharmacology.
[38] M. Kasuga,et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects , 2002, Clinical pharmacology and therapeutics.
[39] Terry R Stouch,et al. Progress in understanding the structure-activity relationships of P-glycoprotein. , 2002, Advanced drug delivery reviews.
[40] Jacques Fellay,et al. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study , 2002, The Lancet.
[41] Yoshinori Morita,et al. MDR1 Genotype-Related Pharmacokinetics of Digoxin After Single Oral Administration in Healthy Japanese Subjects , 2001, Pharmaceutical Research.
[42] R. Kim,et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.
[43] M. Fromm,et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. , 2001, Pharmacogenetics.
[44] V. Armstrong,et al. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. , 2001, Clinical chemistry.
[45] M. Daly,et al. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms , 2001, Nature.
[46] U. Brinkmann,et al. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. , 2001, Pharmacogenomics.
[47] P. Morgan,et al. Role of transport proteins in drug absorption, distribution and excretion , 2001, Xenobiotica; the fate of foreign compounds in biological systems.
[48] A. Seelig,et al. Structure-activity relationship of P-glycoprotein substrates and modifiers. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[49] U Norinder,et al. Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[50] Z. Sauna,et al. Evidence for a requirement for ATP hydrolysis at two distinct steps during a single turnover of the catalytic cycle of human P-glycoprotein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[51] G Ecker,et al. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. , 1999, Biochemical pharmacology.
[52] A. Seelig,et al. Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion , 1998, The Journal of Membrane Biology.
[53] W. Wilson,et al. Genetic polymorphism in MDR-1: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. , 1998, Blood.
[54] Ulf Norinder,et al. Theoretical Calculation and Prediction of Caco-2 Cell Permeability Using MolSurf Parametrization and PLS Statistics , 1997, Pharmaceutical Research.
[55] G Klopman,et al. Quantitative structure-activity relationship of multidrug resistance reversal agents. , 1997, Molecular pharmacology.
[56] Akira Tsuji,et al. Carrier-Mediated Intestinal Transport of Drugs , 1996, Pharmaceutical Research.
[57] A. E. Senior,et al. The catalytic cycle of P‐glycoprotein , 1995, FEBS letters.
[58] U. S. Rao,et al. Mutation of glycine 185 to valine alters the ATPase function of the human P-glycoprotein expressed in Sf9 cells. , 1995 .
[59] J. H. Beijnen,et al. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs , 1994, Cell.
[60] R. Boucher,et al. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase. , 1992, The Journal of biological chemistry.
[61] C. Richardson,et al. Effects of age and sex on piroxicam disposition , 1985, Clinical pharmacology and therapeutics.
[62] S. Carter,et al. Inorganic phosphate assay with malachite green: an improvement and evaluation. , 1982, Journal of biochemical and biophysical methods.
[63] David Neil Cooper,et al. Nature encyclopedia of the human genome , 2003 .
[64] T. Ishikawa,et al. High-Speed Screening and Structure-Activity Relationship Analysis for the Substrate Specificity of P-Glycoprotein (ABCB1)* , 2003 .
[65] Yoshiro Saito,et al. Twelve novel single nucleotide polymorphisms in ABCB1/MDR1 among Japanese patients with ventricular tachycardia who were administered amiodarone. , 2002, Drug metabolism and pharmacokinetics.
[66] P. Joyce,et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression , 2002, The Pharmacogenomics Journal.
[67] M. Zago,et al. Influence of functional MDR1 gene polymorphisms on P-glycoprotein activity in CD34+ hematopoietic stem cells. , 2002, Haematologica.
[68] P. Borst,et al. Mammalian ABC transporters in health and disease. , 2002, Annual review of biochemistry.
[69] A. Sekine,et al. Three hundred twenty-six genetic variations in genes encoding nine members of ATP-binding cassette, subfamily B (ABCB/MDR/TAP), in the Japanese population , 2002, Journal of Human Genetics.
[70] P. Meier,et al. Organic anion transport across the choroid plexus , 2001, Microscopy research and technique.
[71] Elizabeth M. Smigielski,et al. dbSNP: a database of single nucleotide polymorphisms , 2000, Nucleic Acids Res..
[72] I. Pastan,et al. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.
[73] D. de Zeeuw,et al. Transport mechanisms for cationic drugs and proteins in kidney, liver and intestine: implication for drug interactions and cell-specific drug delivery. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[74] W. Hörl,et al. Healthcare systems. An international review. Introduction. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[75] M. Gottesman,et al. Is the multidrug transporter a flippase? , 1992, Trends in biochemical sciences.